Tag
A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.
Measurable residual disease (MRD) testing offers critical insights to tailor allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia, optimizing patient selection, conditioning intensity, and relapse surveillance
The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratif
This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo
Combining genetic risk stratification with measurable residual disease enables precise treatment allocation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia, improving survival outcomes and guiding the use of allogenei
In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.
A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearran
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor
Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.
MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.
Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocy
MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.
